Substance / Medication

Bepridil

Overview

Active Ingredient
bepridil
RxNorm CUI
1436

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The relationship between the plasma concentration of bepridil and its efficacy in the treatment of atrial fibrillation in Japanese patients.
Noda Kumiko, Gotoh Yoshikazu, Tanioka Satoru et al. · Biol Pharm Bull · 2012
PMID: 22687400Trial
Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation.
Murakami Masato, Nakamura Kazufumi, Kusano Kengo F et al. · J Cardiovasc Pharmacol · 2010
PMID: 20625312Trial
Importance of morphological changes in T-U waves during bepridil therapy as a predictor of ventricular arrhythmic event.
Kurokawa Sayaka, Niwano Shinichi, Kiryu Michiro et al. · Circ J · 2010
PMID: 20354335Trial
Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
Imai Shinobu, Saito Fumio, Takase Hidehito et al. · Circ J · 2008
PMID: 18441448Trial
Bepridil for drug-refractory ventricular tachyarrhythmias.
Izumi Daisuke, Chinushi Masaomi, Watanabe Hiroshi et al. · Intern Med · 2007
PMID: 17268127Trial
Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs.
Miyaji Kohei, Tada Hiroshi, Fukushima Kusano Kengo et al. · Circ J · 2007
PMID: 17652890Trial
Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias.
Taguchi Masato, Fujiki Akira, Iwamoto Jotaro et al. · Biol Pharm Bull · 2006
PMID: 16508157Trial
Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
Yasuda Masayuki, Nakazato Yuji, Sasaki Akitoshi et al. · Circ J · 2006
PMID: 16723784Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bepridil (substance)
SNOMED CT
372503006
UMLS CUI
C0005116
RxNorm CUI
1436

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.